The company is under investigation for alleged breach of fiduciary duties and misrepresentation of clinical trial risks. Insiders are accused of downplaying known methodological issues with their Phase 3 trial while promoting it as likely to succeed, which represents potential fraud and shareholder harm.
The company is the subject of a securities class action lawsuit alleging material misrepresentations and concealment of adverse facts regarding its Phase 3 clinical trial for fasedienol. Defendants allegedly made false positive assertions about trial success while concealing negative trial details, resulting in investor damages.
The company is accused of making materially false and misleading statements about its drug development prospects, concealing adverse clinical trial data, and failing to disclose material facts about the PALISADE-3 study, resulting in alleged investor harm and a securities fraud class action lawsuit.
The company is accused of making false and misleading statements about clinical trial results and downplaying risks, leading to investor losses. A securities fraud class action lawsuit has been filed against the company for violations of securities laws.
The company is the subject of a securities class action lawsuit alleging material misrepresentations and concealment of adverse facts regarding its Phase 3 clinical trial for fasedienol. Investors who purchased stock during the class period may have suffered damages due to false and misleading statements about trial success.
The company is the subject of a securities class action lawsuit alleging it provided false and misleading statements about its drug development program while concealing material adverse facts about clinical trial results, resulting in investor damages.
The company faces a class action lawsuit for allegedly disseminating materially false and misleading statements about its Phase 3 trial. The failure of the PALISADE-3 trial to meet primary endpoints resulted in an 80% stock price collapse, indicating significant investor losses and loss of confidence in the company's drug development program.
The company is the subject of a securities class action lawsuit alleging that defendants provided false and misleading statements about the fasedienol drug's trial success while concealing material adverse facts about the Phase 3 PALISADE-3 trial, resulting in investor damages.
Subject of class action lawsuit alleging materially false/misleading statements regarding risks associated with Phase 3 PALISADE-3 trial of fasedienol between April 2024 and December 2025.
Articles that tag VTGN but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
